Incidence of herpes zoster and postherpetic neuralgia in Italian adults aged ≥50 years: A prospective study

Andrea Salvetti, Vincenzo Ferrari, Remigio Garofalo, Pietro Gazzaniga, Alessandro Guerroni, Antonio Metrucci, Aurelio Sessa, Maria Loretta Severi, Giulio Nati, Mauro Ruggeri, Alessandro Rossi, Laura Cappellari, Kusuma Gopala, Roberta Tosatto, Benedetto Simone, Andrea Salvetti, Vincenzo Ferrari, Remigio Garofalo, Pietro Gazzaniga, Alessandro Guerroni, Antonio Metrucci, Aurelio Sessa, Maria Loretta Severi, Giulio Nati, Mauro Ruggeri, Alessandro Rossi, Laura Cappellari, Kusuma Gopala, Roberta Tosatto, Benedetto Simone

Abstract

Herpes zoster (HZ) mainly affects older adults and immunocompromised individuals and is usually characterized by a unilateral painful skin rash. Its most common complication, postherpetic neuralgia (PHN), may cause chronic debilitating pain lasting for months or years. This study (ClinicalTrials.gov Identifier: NCT01772160) aimed to estimate the HZ incidence and the proportion of HZ patients with PHN in the Italian population aged 50 years or older. From 2013 to 2016, HZ-patients were recruited when presenting with acute HZ at 75 reporting general practitioners in Italy, covering 43,875 persons aged ≥50 years. PHN was defined as 'worst pain' rated ≥ 3 on the Zoster Brief Pain Inventory persisting or appearing over 90 days after rash onset. The overall HZ incidence rate per 1000 person-years (PY) was estimated as 6.46 (95% confidence interval [CI]: 5.99-6.95), increasing with age to 9.12/1000 PY (95% CI: 7.50-10.99) in 75-79 year-olds. Among 391 HZ-patients who completed the study, the overall proportion with PHN was 10.23% (95% CI: 7.41-13.67) and the highest proportion was 15.56% (95% CI: 6.49-29.46) for the 75-79 year-olds. Among the 128 patients (32.7%) who reported at least one pre-existing medical condition, 35.9% reported diabetes mellitus and 32.0% reported emotional problems, stress or depression. The study confirms previous findings that HZ and PHN cause an important clinical burden in older Italian adults. It also confirmed the age-related increasing risk of HZ and PHN.

Keywords: Burden of disease; Herpes zoster; Italy; Postherpetic neuralgia; Primary care setting; Prospective study.

Figures

Fig. 1
Fig. 1
Flow chart. HZ = Herpes zoster; ZBPI = zoster brief pain inventory.
Fig. 2
Fig. 2
Focus on the patient.

References

    1. Alicino C., Trucchi C., Paganino C., Barberis I., Boccalini S., Martinelli D., Pellizzari B., Bechini A., Orsi A. Incidence of herpes zoster and post-herpetic neuralgia in Italy: results from a 3-years population-based study. Hum Vaccin Immunother. 2017;13:399–404.
    1. Ansaldi F., Trucchi C., Alicino C., Paganino C., Orsi A., Icardi G. Real-world effectiveness and safety of a live-attenuated herpes Zoster vaccine: a comprehensive review. Adv. Ther. 2016;33:1094–1104.
    1. Bricout H., Perinetti E., Marchettini P., Ragni P., Zotti C.M., Gabutti G., Volpi A., Franco E. Burden of herpes zoster-associated chronic pain in Italian patients aged 50 years and over (2009-2010): a GP-based prospective cohort study. BMC Infect. Dis. 2014;14:637.
    1. Cohen J.I. Herpes zoster. N. Engl. J. Med. 2013;369:1766–1767.
    1. Coplan P.M., Schmader K., Nikas A., Chan I.S., Choo P., Levin M.J., Johnson G., Bauer M., Williams H.M. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J. Pain. 2004;5:344–356.
    1. Di Legami V., Gianino M.M., Ciofi degli Atti M., Massari M., Migliardi A., Tomba G.S., Zotti C., Zoster Study G. Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. Vaccine. 2007;25:7598–7604.
    1. Drolet M., Brisson M., Schmader K.E., Levin M.J., Johnson R., Oxman M.N., Patrick D., Blanchette C., Mansi J.A. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010;182:1731–1736.
    1. EMA . 2018. Shingrix, INN-Herpes zoster vaccine (recombinant, adjuvanted) (Last Accessed May 9, 2019)
    1. Epicentro 2019.
    1. EseMed 2019.
    1. Gabutti G., Serenelli C., Sarno O., Marconi S., Corazza M., Virgili A. Epidemiologic features of patients affected by herpes zoster: database analysis of the Ferrara University Dermatology Unit, Italy. Med. Mal. Infect. 2010;40:268–272.
    1. Gater A., Abetz-Webb L., Carroll S., Mannan A., Serpell M., Johnson R. Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study. BMC Infect. Dis. 2014;14
    1. Gershon A.A., Gershon M.D. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin. Microbiol. Rev. 2013;26:728–743.
    1. Gershon A.A., Gershon M.D., Breuer J., Levin M.J., Oaklander A.L., Griffiths P.D. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J. Clin. Virol. 2010;48(Suppl. 1):S2–S7.
    1. Gialloreti L.E., Merito M., Pezzotti P., Naldi L., Gatti A., Beillat M., Serradell L., di Marzo R., Volpi A. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect. Dis. 2010;10
    1. Johnson R.W. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines. 2010;9:21–26.
    1. McElhaney J.E. Herpes zoster: a common disease that can have a devastating impact on patients' quality of life. Expert Rev Vaccines. 2010;9:27–30.
    1. Ministero della Salute - Italia Piano nazionale prevenzione vaccinale. 2017.
    1. Pinchinat S., Cebrian-Cuenca A.M., Bricout H., Johnson R.W. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect. Dis. 2013;13
    1. Schmader K.E., Sloane R., Pieper C., Coplan P.M., Nikas A., Saddier P., Chan I.S., Choo P., Levin M.J. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin. J. Pain. 2007;23:490–496.
    1. Schmidt-Ott R., Schutter U., Simon J., Nautrup B.P., von Krempelhuber A., Gopala K., Anastassopoulou A., Guignard A., Curran D. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged >/=50 years: a prospective study. J. Inf. Secur. 2018;76:475–482.
    1. Torcel-Pagnon L., Bricout H., Bertrand I., Perinetti E., Franco E., Gabutti G., Volpi A. Impact of underlying conditions on zoster-related pain and on quality of life following zoster. J. Gerontol. A Biol. Sci. Med. Sci. 2017;72:1091–1097.
    1. United Nations Department of Economic and Social Affairs World Population Prospects, The 2017 Revision. 2017.
    1. US-FDA . 2006. Highlights of prescribing information – Zostavax. (Last Accessed May 9, 2019)
    1. US-FDA . 2017. Highlights of prescribing information – Shingrix. (Last Accessed May 9, 2019)
    1. Varghese L., Standaert B., Olivieri A., Curran D. The temporal impact of aging on the burden of herpes zoster. BMC Geriatr. 2017;17
    1. Yanni E.A., Ferreira G., Guennec M., El Hahi Y., El Ghachi A., Haguinet F., Espie E., Bianco V. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012. BMJ Open. 2018;8
    1. Yawn B.P., Saddier P., Wollan P.C., St Sauver J.L., Kurland M.J., Sy L.S. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin. Proc. 2007;82:1341–1349.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する